Do renin–angiotensin system inhibitors influence the recurrence, metastasis, and survival in cancer patients?
Do renin–angiotensin system inhibitors influence the recurrence, metastasis, and survival in cancer patients?
复制标题
肾素-血管紧张素系统抑制剂是否影响癌症患者的复发、转移和生存？
作者：
Hong Sun;Tao Li;R. Zhuang;Weimin Cai;Yuan
背景：肾素-血管紧张素系统抑制剂（RAS抑制剂）是具有潜在抗肿瘤作用的抗高血压药物。然而，关于 RAS 抑制剂对癌症患者生存的影响，各种研究得出了相互矛盾的结果。本研究的目的是通过荟萃分析评估 RAS 抑制剂对癌症患者复发、转移和生存的影响。方法：从建立到2016年12月，系统地检索了PubMed、Web of Science、EMBASE和Cochrane Library。计算了合并风险比（HR）及其95%置信区间（95% CI），以评估RAS抑制剂与癌症患者复发、转移和生存之间的关联。结果：本荟萃分析纳入了 55 项符合条件的研究。结果显示，总生存期（OS）（HR = 0.82；95% CI：0.77–0.88；P < 0.001）、无进展生存期（HR = 0.74；95% CI：0.66–0.84；P < 0.001）和无病生存期均显着改善。 RAS 抑制剂使用者与非使用者相比（HR = 0.80；95% CI：0.67–0.95；P = 0.01）。亚组分析显示，RAS 抑制剂对 OS 的影响取决于癌症类型或不同的 RAS 抑制剂。结论：这项荟萃分析表明 RAS 抑制剂可以改善癌症患者的生存率，并且取决于癌症类型和 RAS 抑制剂的类型。
Background: Renin–angiotensin system inhibitors (RAS inhibitors) are antihypertensive agents with potential antitumor effects. However, various studies have yielded conflicting results on the influence of RAS inhibitors on survival of cancer patients. The aim of this study was to evaluate the effect of RAS inhibitors on recurrence, metastasis, and survival in cancer patients through a meta-analysis. Methods: PubMed, Web of Science, EMBASE, and Cochrane Library were systematically searched from inception to December 2016. The pooled hazard ratio (HR) with its 95% confidence interval (95% CI) was calculated to evaluate the association between RAS inhibitors and recurrence, metastasis, and survival in cancer patients. Results: Fifty-five eligible studies were included in the present meta-analysis. Results showed that there were significant improvements in overall survival (OS) (HR = 0.82; 95% CI: 0.77–0.88; P < 0.001), progression-free survival (HR = 0.74; 95% CI: 0.66–0.84; P < 0.001), and disease-free survival (HR = 0.80; 95% CI: 0.67–0.95; P = 0.01) in RAS inhibitor users compared with nonusers. Subgroup analyses revealed that the effect of RAS inhibitors on OS depended on the cancer type or different RAS inhibitors. Conclusion: This meta-analysis suggests that RAS inhibitors could improve the survival of cancer patients and depend on cancer type and types of RAS inhibitors.
登录
查看更多内容
影响因子：
3
作者：
Williams GR;Mackenzie A;Magnuson A;Olin R;Chapman A;Mohile S;Allore H;Somerfield MR;Targia V;Extermann M;Cohen HJ;Hurria A;Holmes H
通讯作者：
Holmes H
影响因子：
5
作者：
Engineer, Diana R.;Burney, Basil O.;Garcia, Jose M.
通讯作者：
Garcia, Jose M.
影响因子：
45.3
作者：
Melhem-Bertrandt, Amal;Chavez-MacGregor, Mariana;Gonzalez-Angulo, Ana-Maria
通讯作者：
Gonzalez-Angulo, Ana-Maria
血管紧张素 II 产生的新血管形成。
DOI：
--
发表时间：
1985
期刊：
The Journal of laboratory and clinical medicine
影响因子：
--
作者：
Fernandez,LA;Twickler,J;Mead,A
通讯作者：
Mead,A